Timing. Relevance. Relationships.
Fundz is the only platform that reads more than a dozen real‑time signals all day, every day, so you know about new funding, new executives and new contracts within minutes of them happening, not days or weeks later like the databases you’re used to. It then combines the signals on each company, scores every company against what you offer, and weaves in your own network, so you discover new accounts first and work existing ones better.
Each morning you get the ones worth your time right now: who to reach, why now, and who you already know there. Now it answers in Claude too: ask for today’s leads, then write the note in the same window.
Trusted by
Acquiring Company
Voyager Acquisition
Acquired Company
VERAXA Biotech
New York
ZurichFinancial ServicesHealth CareFinanceVenture CapitalMedicalFintechBiotechnologyHealth CareDescription
VERAXA Biotech AG announced that its shareholders approved the merger with Voyager Acquisition Corp. The merger will involve the issuance of new shares to the SPAC. This strategic move aims to enhance VERAXA's capabilities and market presence.
Fundz sees it the moment Voyager Acquisition makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired VERAXA Biotech?
VERAXA Biotech was acquired by Voyager Acquisition, based in New York. The deal was reported on February 27, 2026. Voyager is a special purpose acquisition company that focuses on revolutionizing the healthcare sector through mergers and business combinations. Voyager Acquisition is privately held and operates in Financial Services.
When did Voyager Acquisition acquire VERAXA Biotech?
Voyager Acquisition's acquisition of VERAXA Biotech was reported on February 27, 2026. VERAXA Biotech AG announced that its shareholders approved the merger with Voyager Acquisition Corp. The merger will involve the issuance of new shares to the SPAC. This strategic move aims to enhance VERAXA's capabilities and market presence. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does VERAXA Biotech do?
VERAXA Biotech is a Swiss biotechnology company focused on developing innovative oncology therapies. The company specializes in a proprietary BiTAC platform and is advancing various cancer treatment programs. It is publicly traded (VRXA), operating in Biotechnology, and is based in Zurich.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.